A day of celebration that Forestville Elementary School has fostered for more than four decades was held last month. The ...

There are three main types of ovarian cancer: epithelial, germ cell, and stromal. Learn about each type’s defining ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...

Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has accepted Talzenna (talazoparib) in combination with ...

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...

An extensive tumor genomic analysis of individuals with ovarian cancer, led by researchers from Huntsman Cancer Institute at ...

Research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Nuvation Bio in a report released on Monday, March 10th. HC Wainwright analyst R. Burns now expects ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses Lynparza’s role in reducing the risk of invasive disease recurrence or death in HR-positive breast cancer patients.

BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...

An extensive tumor genomic analysis of individuals with ovarian cancer, led by researchers from Huntsman Cancer Institute at the University of Utah ...